Horizon, Centauri form joint venture, 5/16

May 2016—Horizon Discovery Group has formed an immuno-oncology joint venture, Avvinity Therapeutics, with Centauri Therapeutics, a U.K.-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases. This transaction represents part of Horizon’s strategy to invest more than $14 million to identify the next generation of molecular and cellular cancer therapeutics.

Avvinity will combine Horizon’s gene editing, immunology, oncology, and drug discovery capabilities with Centauri’s Alphamer technology to provide a proprietary platform to discover and develop novel immunooncology therapeutics, for both solid tumors and leukemias. Avvinity will be managed jointly by Horizon and Centauri as part of Horizon’s Research Biotech business

Horizon Discovery, +44 (0) 1223 655 580

Centauri Therapeutics, +44 (0) 1304 728610